The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
History shows that the market's biggest winners often have an RS Rating of over 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is DexCom Stock A Buy?
The stock, which is on both the IBD 50 and IBD 50 screens, is currently at the top end of buying range after clearing a flat base with 132.03 buy point. See if you can catch this medical stock before it gets extended.
The glucose monitor maker showed 47% earnings growth in the latest quarterly report. Revenue gains came in at 27%. Keep an eye out for the company's next round of numbers on or around Apr. 25.
DexCom stock earns the No. 2 rank among its peers in the Medical-Products industry group. DexCom is the top-ranked stock within the group.
